育龄女性初级保健中高风险药物处方与避孕记录情况
该回顾性研究在2个家庭医学诊所评估13至45岁非妊娠女性中高风险致畸药物的处方及避孕记录情况。共纳入3956名女性,988名(25%)被处方至少1种高风险药物,其中超过半数(55%)没有避孕措施记录。25岁以下女性在接受致畸药物时获得避孕管理的几率更低(调整OR 0.47,95%CI 0.34-0.66)。
要点
- 育龄女性中25%被处方高风险药物,其中55%无避孕记录。
- 最常见高风险药物为昂丹司琼(73%)和赖诺普利(20%)。
- 25岁以下女性接受致畸药物时避孕管理几率更低。
核心结论
- 家庭医学环境中,25%的育龄女性被处方高风险药物,其中超过半数无避孕管理证据。
- 年轻女性在接受致畸药物时获得避孕管理的几率更低。
研究设计与样本
- 回顾性研究,在2个家庭医学诊所评估13至45岁非妊娠女性,共纳入3956名。
- 使用多变量逻辑回归模型估计接受致畸药物与避孕之间的年龄调整关联,并进行排除昂丹司琼的亚组分析。
主要发现
- 988名(25%)被处方至少1种高风险药物,最常见为昂丹司琼(n=724,73%)和赖诺普利(n=195,20%)。
- 处方高风险药物的女性中55%没有避孕措施记录。
- 排除昂丹司琼后,10%的人群被处方至少1种高风险药物,其中62%也没有避孕措施记录。
- 25岁以下女性在接受致畸药物时获得避孕的几率降低(调整OR 0.47,95%CI 0.34-0.66)。
关键数值与推荐
- 高风险药物包括昂丹司琼和赖诺普利等潜在致畸药物。
- 避孕形式包括药物、绝育或绝经后状态。
临床怎么用
- 处方者应意识到致畸药物风险,并就风险进行咨询,定期评估患者的生育计划。
- 对育龄女性处方高风险药物时,应评估并记录避孕措施。
局限性
- 回顾性研究设计,仅基于2个家庭医学诊所的数据。
- 避孕记录可能不完整,未反映实际使用情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: During pregnancy, women may be exposed to teratogenic medications resulting in a risk of complications and poor maternal-fetal outcomes. The objective of this study was to evaluate the prescription of teratogenic medications in women of childbearing age and the associated prescription of contraception in the primary care setting. METHODS: The use of high-risk, potentially teratogenic, medications was retrospectively evaluated in women of childbearing age (13 to 45 years old) at 2 family medicine practices. Charts were reviewed for medication use and whether patients received a form of birth control (medication, sterilization, or postmenopausal) with the teratogenic medications. A multivariable logistic regression model was used to estimate the age-adjusted association between receiving a teratogenic medication and contraception. A subgroup analysis excluding ondansetron was also performed. RESULTS: A total of 3,956 nonpregnant women were included with 988 (25%) prescribed at least 1 high-risk medication. The most commonly prescribed high-risk medications were ondansetron (n = 724, 73%) and lisinopril (n = 195, 20%). More than half (55%) of the women prescribed a high-risk medication were without a form of birth control. When ondansetron was excluded, 10% of the population was prescribed at least 1 high-risk medication with 62% also without a form of birth control. Women less than 25 years of age had decreased odds of receiving contraception when prescribed a teratogenic medication (adjusted odds ratio, 0.47; 95% confidence interval, 0.34-0.66). CONCLUSION: In a family medicine setting, 25% of women of childbearing age were prescribed a high-risk medication with over half not having evidence of contraception management. Interestingly, younger age women had lower odds of receiving contraceptive management when prescribed high-risk medications. Prescribers should be aware of and counsel on the risks of teratogenic medications and regularly evaluate reproductive plans for patients.
引用
- Panchal BD, Cash R, Moreno C, et al. High-Risk Medication Prescriptions in Primary Care for Women Without Documented Contraception. J Am Board Fam Med. 2019. PMID: 31300567. doi:10.3122/jabfm.2019.04.180281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。